The Accomplishments & History of Lindsay Rosenwald
Today, the biotechnology industry is evolving rather quickly and Dr. Lindsay Rosenwald plays a key role in its growth. Dr. Rosenwald has invested in a long and diverse list of companies, including research centers and companies developing new drugs.
Dr. Lindsay Rosenwald has gained a respectable standing on Wall Street where he is a venture capitalist and hedge fund manager. For almost two decades he has also been building an uncompromising reputation in life-sciences and medicine research. He has always played a key role in R&D breakthroughs in biotechnology and healthcare. As a result of the way he combines medicine with finance, Dr. Rosenwald has the expertise to both launch new initiatives in research as well as locate ideal companies to invest in. His work has helped to extend the reaches of healthcare, indirectly benefiting millions of people the world over. It would be difficult to find another individual who has excelled as well as he in these industries.
During his stunning career, almost two decades long, Dr. Lindsay A. Rosenwald is responsible for creating and recapitalizing numerous public and private companies in the life-science and biotech industries.
Rosenwald finished his high school education in 1973 at Abington. Thereafter, he attended Pennsylvania State University, graduating with a degree in Finance. After Penn State, he received his medical degree from the Temple University School of Medicine and went on to meet the requirements of his medical internship at Abington Medical Hospital. For a short while he had his own private medical practice before moving on to other things. He carved his way successfully through Wall Street, combining his knowledge in both medicine and finance to form new ideas.
Between the years of 1994 and 2007, Rosenwald took on the role of executive director at the Aries Funds which has invested more than $1 billion into healthcare companies that show promise. Rosenwald also directed the Orion Fund from 2002 to 2006, which invested only in the biotech industry, especially private investments in public equity.
Dr. Rosenwald also created the Rosenwald Foundation, a non-profit that is committed to supporting scientific, healthcare and educational companies.
A unique mixture of finance and medicine has led Rosenwald down a path of discovery in the medicine, biotechnology and life sciences industries, where he has had the opportunity to explore new and innovative projects.
Today Dr. Rosenwald is a director at the Republican Jewish Coalition. He is also the president of Paramount Group which concentrates its efforts on investment banking, R&D, and equity management in the industries of life-science and biotechnology. One of his most recent enterprises is the OpusPoint Partners, LLC, established in 2009 with the purpose of supporting innovations in life-sciences and biotechnology. The company is dedicated to technological breakthroughs that will influence and guide today’s life-sciences and biotechnology companies.
Some of Dr. Lindsay Rosenwald and his team’s most admirable accomplishments include the funding they have offered various companies and drug candidates showing great promise. One such company is Cougar Biotechnology Inc., based in L.A., which focuses on cancer treatment. One of the company’s recent developments was Abiraterone, a drug that tackles aggressive prostate cancer. The company was sold to Johnson & Johnson for almost $1 billion in 2009 after a negotiation with Dr. Rosenwald.
It is the mandate of OpusPoint Partners and Dr. Rosenwald to continue making progress with projects like these. With their work they intend to profoundly alter the fields of medicine and the life sciences, while giving hope to millions of people across the globe.
By creating solid relationships and building upon their past experience, Dr. Rosenwald and OpusPoint Partners will pave the way to a bright future. They blaze ahead leaving a trail of revolutionary successes. Dr. Rosenwald is a true leader in healthcare and biotechnology. He has a number of firsts to his name. He was the first to put an investment into the first obesity drug in the US market. He was also the first to start the first stem cell company that deals with public trading. In addition, the first public gene therapy company developed with his contribution and so did the first cancer vaccine available to the public.
The present aim for Dr. Lindsay Rosenwald and OpusPoint Partners is to create a solid network with other leaders that espouse the same values and business approaches and who are dedicating to discovering and investing in ground-breaking technologies across these fields.
With this kind of commitment, strategy and expert knowledge, OpusPoint Partners and its founders, Dr. Rosenwald and Michael S. Weiss, have a brilliant and steady path lying ahead of them. Their investments have the ability to completely alter the way in which we manage disease.
Related posts:
- OpusPoint Partners: Preparing for a New Approach to Life Science and Healthcare
- OpusPoint Partners: Changing the Face of Life Science and Healthcare
- Lindsay Rosenwald Investing in Future ofLife Sciences and Healthcare
- Lindsay Rosenwald A Step Ahead In Investment Of Healthcare & Lifescience
- Lindsay Rosenwald – A Novel Invention Leads the Road